PMID- 8923574
OWN - NLM
STAT- MEDLINE
DCOM- 19970325
LR  - 20190726
IS  - 0033-3158 (Print)
IS  - 0033-3158 (Linking)
VI  - 127
IP  - 4
DP  - 1996 Oct
TI  - Initial monoamine oxidase-A inhibition by moclobemide does not predict the 
      therapeutic response in patients with major depression. A double blind, 
      randomized study.
PG  - 370-6
AB  - It is generally accepted that the clinical efficacy of monoamine oxidase 
      inhibitors (MAOI) is related to inhibition of this enzyme. In order to evaluate 
      the predictive ability of monoamine oxidase-A inhibition for therapeutic 
      efficacy, the start of treatment effects of moclobemide, a selective, reversible 
      monoamine oxidase-A inhibitor, on plasma concentrations of monoamines and 
      monoamine metabolites were determined. The plasma levels of 
      3,4-dihydroxyphenylglycol (DHPG, deaminated metabolite of noradrenaline), 
      5-hydroxyindoleacetic acid (5-HIAA, deaminated metabolite of serotonin), 
      3,4-dihydroxyphenylacetic acid and homovanillic acid (DOPAC and HVA, deaminated 
      metabolites of dopamine), L-dihydroxyphenylalanine (L-dopa) and noradrenaline 
      were investigated and related to treatment outcome. This was a randomized double 
      blind parallel group study in 47 patients with criteria of major depression 
      according to DSM III R. Moclobemide 300 mg/day, 450 mg/day or 600 mg/day was 
      administered continuously for 6 weeks. Plasma concentrations of monoamine 
      metabolites and monoamines were determined just before treatment by moclobemide, 
      4 h after the first dose, 24 h after the first dose, before the first dose on day 
      7, and 4 h after the first dose, on day 7. Each moclobemide dose improved 
      depression as measured by MADRS (Montgomery-Asberg Depression Rating scale) but 
      there was no difference between the three doses. Moclobemide dose-dependently 
      reduced plasma concentration of DHPG, L-dopa and HVA. No dose-dependent treatment 
      effect was observed for plasma 5-HIAA, noradrenaline and DOPAC. The clinical 
      outcome as defined by the final MADRS score was not related to any start of 
      treatment changes in plasma monoamine metabolites reflecting inhibition of MAO-A. 
      It is concluded that monoamine oxidase-A inhibition at the beginning of the 
      treatment does not predict clinical outcome.
FAU - Radat, F
AU  - Radat F
AD  - Department of Psychiatry, Hopital Saint Antoine, Paris, France.
FAU - Berlin, I
AU  - Berlin I
FAU - Spreux-Varoquaux, O
AU  - Spreux-Varoquaux O
FAU - Elatki, S
AU  - Elatki S
FAU - Ferreri, M
AU  - Ferreri M
FAU - Puech, A J
AU  - Puech AJ
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Psychopharmacology (Berl)
JT  - Psychopharmacology
JID - 7608025
RN  - 0 (Antidepressive Agents)
RN  - 0 (Benzamides)
RN  - 0 (Biomarkers)
RN  - 0 (Monoamine Oxidase Inhibitors)
RN  - 102-32-9 (3,4-Dihydroxyphenylacetic Acid)
RN  - 534-82-7 (Methoxyhydroxyphenylglycol)
RN  - 54-16-0 (Hydroxyindoleacetic Acid)
RN  - PJ0Y7AZB63 (Moclobemide)
RN  - UEH9K539KJ (3,4-dihydroxyphenylglycol)
SB  - IM
MH  - 3,4-Dihydroxyphenylacetic Acid/blood
MH  - Adult
MH  - Antidepressive Agents/*therapeutic use
MH  - Benzamides/*therapeutic use
MH  - Biomarkers/blood
MH  - Depressive Disorder/blood/*drug therapy
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Hydroxyindoleacetic Acid/blood
MH  - Male
MH  - Methoxyhydroxyphenylglycol/analogs & derivatives/blood
MH  - Middle Aged
MH  - Moclobemide
MH  - Monoamine Oxidase Inhibitors/*therapeutic use
EDAT- 1996/10/01 00:00
MHDA- 1996/10/01 00:01
CRDT- 1996/10/01 00:00
PHST- 1996/10/01 00:00 [pubmed]
PHST- 1996/10/01 00:01 [medline]
PHST- 1996/10/01 00:00 [entrez]
AID - 10.1007/s002130050100 [doi]
PST - ppublish
SO  - Psychopharmacology (Berl). 1996 Oct;127(4):370-6. doi: 10.1007/s002130050100.